Astellas' regenerative medicine research unit begins operations

04/1/2014 | PMLive.com (U.K.)

Astellas Pharma announced that its regenerative medicine unit has begun operations and will lead the company's research and development of cell-based therapies. Astellas has been working with Cytori Therapeutics on the use of fat-derived stem cells and has partnered with Switzerland's ClearPath Development on vaccines.

View Full Article in:

PMLive.com (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD